Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient Outcomes with Current Generation of Stents

 Largest Prospective Study Shows IVUS-Guided Stent Placement Improves Patient
                  Outcomes with Current Generation of Stents

3,349 Patient, Multi-Center IVUS Sub-study Shows IVUS Significantly Reduces
Stent Thrombosis and MI

PR Newswire

SAN DIEGO, Nov. 14, 2012

SAN DIEGO, Nov. 14, 2012 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a
leading developer and manufacturer of precision guided therapy tools designed
to enhance the diagnosis and treatment of coronary and peripheral vascular
disease, today announced that results from the largest study of its kind show
that stent procedures guided by intravascular ultrasound (IVUS) resulted in
better patient outcomes and fewer complications at 30 days and 12 months
compared to procedures without IVUS, and were safe.

Enrolling 3,349 patients, the IVUS sub-study is part of the Cardiovascular
Research Foundation's (CRF) ADAPT-DES study (Assessment of Dual AntiPlatelet
Therapy with Drug-Eluting Stents), a prospective, multi-center registry of
8,583 patients with coronary artery disease undergoing percutaneous coronary
intervention (PCI) with drug-eluting stents (DES). Results of the ADAPT-DES
IVUS sub-study were presented at the 24th Annual Transcatheter Cardiovascular
Therapeutics (TCT) scientific symposium sponsored by CRF.

"The ADAPT-DES IVUS sub-study provides the strongest evidence to date that use
of IVUS to guide optimizing placement improves patient outcomes," said Gregg
W. Stone, M.D., FACC, FSCAI, Professor of Medicine at Columbia University
College of Physicians and Surgeons and Director of Cardiovascular Research and
Education at the Center for Interventional Vascular Therapy at New
York-Presbyterian Hospital/Columbia University Medical Center. "Previously,
the additive value of IVUS as an independent predictor of stent thrombosis,
myocardial infarction (MI) and death had not been assessed in a large-scale,
prospective, multi-center registry which had sufficient power to address these
issues."

Bernhard Witzenbichler, M.D., Head of Interventional Cardiology at Charite
University of Medicine Berlin in Berlin, Germany stated, "In the study, we
found that IVUS guidance changed the therapy in more than two-thirds of the
cases, indicating that it helped the interventionalist choose a better and
more personalized treatment path for the patient. These results add a robust
new plank to the already considerable evidence base supporting IVUS guidance
as the standard of care for stent procedures."

One-year results from the ADAPT-DES study—which is designed to determine the
frequency, timing and correlates (clinical, angiographic and IVUS) of DES
thrombosis and the relationship of aspirin and/or clopidogrel
hyporesponsiveness, and general platelet reactivity to early and late DES
thrombosis—was reported in a Plenary Session on Thursday, Oct. 25 by Gregg W.
Stone, MD,  at TCT.

Key Study Results
When compared to procedures without IVUS, IVUS-guided procedures demonstrated
a 50% reduction in the incidence of stent thrombosis (a blood clot on the
surface of a stent) and 33% reduction in MI that began as soon as 30 days post
procedure, and continued for 12 months.

No safety issues were identified in the IVUS-guided procedures in the trial,
as there was no increase in peri-procedural MI. IVUS cases were not associated
with a significant increase in the usage of stents. The majority of stents
used in this study were of the latest generation and marketed globally.

"The ADAPT-DES IVUS results at 30 days and 12 months meaningfully advance the
field of interventional cardiology, and also have important implications for
the healthcare delivery system as institutions seek strategies to improve the
quality of care and avoid penalties imposed by the new CMS 30-day readmission
policy," said Scott Huennekens, President and Chief Executive Officer, Volcano
Corporation. "With the insight our technologies such as IVUS provide, Volcano
can help physicians and healthcare institutions answer the growing demand for
truly personalized medicine that is appropriate, evidence-based and
accountable."

Volcano's Eagle Eye^® Gold IVUS catheters were used in all sub-study patients
at the initiation of the sub-study and in follow-up assessments. Analysis
included assessment of lesion morphology by using both traditional grayscale
IVUS and Volcano's proprietary VH^® IVUS tissue characterization technology.

About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a
broad suite of technologies that make imaging and therapy simpler, more
informative and less invasive. Its products empower physicians around the
world with a new generation of analytical tools that deliver more meaningful
information - using sound and light as the guiding elements. Founded in
cardiovascular care and expanding into other specialties, Volcano is changing
the assumption about what is possible in improving patient outcomes by
combining imaging and therapy together.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995. Any statements in
this press release regarding Volcano's business that are not historical facts
may be considered "forward-looking statements." Forward-looking statements are
based on management's current expectations and are subject to risks and
uncertainties that may cause Volcano's actual results to differ materially and
adversely from statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ include the effect of
competitive factors and the company's reactions to those factors; purchasing
decisions with respect to the company's products; the pace and extent of
market adoption of the company's products and technologies; uncertainty in the
process of obtaining regulatory approval or clearance for Volcano's products
or devices; the success of Volcano's growth strategies; timing and achievement
of product development milestones; outcome of ongoing or future litigation;
the impact and benefits of market development; our ability to protect our
intellectual property; dependence upon third parties; unexpected new data,
safety and technical issues; market conditions and other risks inherent to
medical and/or telecom device development and commercialization. These and
additional risks and uncertainties are more fully described in Volcano's
filings made with the Securities and Exchange Commission, including our most
recent quarterly report on Form 10-Q, and other filings made with the
Securities and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are made.
Volcano disclaims any obligation to update any forward-looking statements to
reflect new information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation

Website: http://www.volcanocorp.com
Website: http://www.tctconference.com
Contact: Edrienne Brandon, Media Contact, +1-858-720-4136,
brandon@volcanocorp.com; Neal Rosen, Investor Contact, +1-650-458-3014,
nrosen@volcanocorp.com